Current guidelines for thienopyridines in PCI note the lack of RCT data for higher loading doses. Read Dr Wang's lowdown on loading doses, including recent presentations from the 2008 SCAI-ACCi2 meeting. Then watch Drs Mehta and Mehran discuss where CURRENT-OASIS-7 will fit in.

Join Dr Gregg Stone as he presents the most comprehensive DES/BMS meta-analysis ever! Expert faculty Drs Hermiller, Moses, Popma and Turco also debate current DES safety and efficacy data.

If we're all looking at the same data, why do the European and US guidelines for the treatment of ACS differ in terms of initiation, dosing, and choices of pharmacological therapies? Drs Ohman, Montalescot, Pollack and Fox discuss the similarities and differences.

What is the future of adjunctive pharmacology given the results of the HORIZONS and TRITON trials?

Trading safety for efficacy with antiplatelet agents

Over the past year, much debate has been given to the issue of drug-eluting stents (DES) and the risk of restenosis. Trials like COURAGE enrolled patients with chronic stable angina and looked to examine optimal medical therapy versus an invasive strategy. Despite much lively discussion surrounding the results of COURAGE, questions still linger regarding the use of invasive (DES or BMS) versus OMT and what treatment is best for patients with coronary heart disease. This program addresses these issues in an evidence-based manner. Please join Drs Feldman, Kereiakes, Davidson and Farkouh as they untangle recent clinical trial data.